Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

Cited by (387)

Items 101–200 of 387

1. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
   Kuniaki Shirao, Toshirou Nishida, Toshihiko Doi · 2009 · Investigational New Drugs
2. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
   Peter Reichardt, George D. Demetri, Hans A. J. Gelderblom et al. · 2016 · BMC Cancer
3. Phosphatases: The New Brakes for Cancer Development?
   Qingxiu C. Zhang, Francois X. Claret · 2011 · Enzyme Research
4. Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
   Denian Wang, Fei Xiao, Zhongxue Feng, Min Li, Lingmiao Kong, Lüping Huang, Yonggang Wei, Hongyu Li, Fei Liu, Haili Zhang et al. · 2020 · Breast Cancer Research
5. Sunitinib
   Emma D. Deeks, Gillian M. Keating · 2006 · Drugs
6. mTOR signaling as a molecular target for the alleviation of Alzheimer's disease pathogenesis
   Deepthi Rapaka, Veera Raghavulu Bitra, Siva Reddy Challa, Paul Chukwuemeka Adiukwu · 2022 · Neurochemistry International
7. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
   Charles S. Harmon, Samuel E. DePrimo, Robert A. Figlin, Gary R. Hudes, Thomas E. Hutson, Marc Dror Michaelson, Sylvie Négrier, Sindy T. Kim, Xin Huang, James Andrew Williams et al. · 2013 · Cancer Chemotherapy and Pharmacology
8. Multidrug Resistance Protein 2 Implicates Anticancer Drug-Resistance to Sorafenib
   Yoshihiko Shibayama, Kou Nakano, Hiroshi Maeda, Miyuki Taguchi, Ryuji Ikeda, Mitsuru Sugawara, Ken Iseki, Yasuo Takeda, Katsushi Yamada · 2011 · Biological and Pharmaceutical Bulletin
9. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer
   Olivier Guérin, Patricia Formento, Cristiana Lo Nigro, Paul M Hofman, Jean–Louis Fischel, Marie-Christine Étienne-Grimaldi, Marco Carlo Merlano, J-M Ferrero, Gerard Alain Milano · 2007 · Journal of Cancer Research and Clinical Oncology
10. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook
    John F. Deeken, Liron Pantanowitz, Bruce Jeffrey Dezube · 2009 · Current Opinion in Oncology
11. Dynamic Switch of Negative Feedback Regulation in Drosophila Akt–TOR Signaling
    Lutz Kockel, Kimberly S. Kerr, Michael Melnick, Katja Brückner, Matthias Hebrok, Norbert Perrimon · 2010 · PLoS Genetics
12. mTOR signaling in human cancer
    Joan Albanell, Alba Dalmases, Ana Rovira, Federico Rojo · 2007 · Clinical & Translational Oncology
13. Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex
    Katarzyna Kotulska, Julita Borkowska, Marek Mandera · 2014 · Child s Nervous System
14. Small Cell Carcinoma
    Elisabeth M. Brambilla · 2008 · Molecular pathology library
15. The role of cell signaling in poxvirus tropism: The case of the M-T5 host range protein of myxoma virus
    Steven J. Werden, Grant McFadden · 2007 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
16. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD
    Yuria Saito, Yuko Tanaka, Yuichi Aita, Kiyo‐aki Ishii, Tatsuhiko Ikeda, Kazumasa Isobe, Yasushi Kawakami, Hitoshi Shimano, Hisato Hara, Kazuhiro Takekoshi · 2011 · American Journal of Physiology-Endocrinology and Metabolism
17. Molecular Cross-talk between MEK1/2 and mTOR Signaling during Recovery of 293 Cells from Hypertonic Stress
    Susanne Naegele, Simon Morley · 2004 · Journal of Biological Chemistry
18. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial
    Aaron I. Vinik, Andrew Bottomley, Beata Korytowsky et al. · 2016 · Targeted Oncology
19. Design and characterization of ascorbic acid based therapeutic deep eutectic solvent as a new ion-gel for delivery of sunitinib malate
    Masumeh Mokhtarpour, Hemayat Shekaari, Ali Shayanfar · 2020 · Journal of Drug Delivery Science and Technology
20. Spatiotemporal Characterization of mTOR Kinase Activity Following Kainic Acid Induced Status Epilepticus and Analysis of Rat Brain Response to Chronic Rapamycin Treatment
    Matylda Macias, Magdalena Błażejczyk, Paulina Kaźmierska, Bartosz Caban, Agnieszka Skalecka, Bartosz Tarkowski, Anna Rodo, Jan Konopacki, Jacek Jaworski · 2013 · PLoS ONE
21. Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors
    Pascal Wolter, Benoit Beuselinck, Steven Pans, Patrick Schöffski · 2009 · Acta Oncologica
22. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms
    Yuki Mizuno, Atsushi Kudo, Takumi Akashi et al. · 2018 · Journal of Cancer Research and Clinical Oncology
23. Angiogenesis in cutaneous disease: Part I
    Amy Nguyen, Van Hoang, Vivian T. Laquer, Kristen M. Kelly · 2009 · Journal of the American Academy of Dermatology
24. A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors
    Christopher J. Sweeney, Elena Gabriela Chiorean, Claire F. Verschraegen et al. · 2010 · Journal of Clinical Oncology
25. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex
    Maria M. Alves, Gwenny Manel Fuhler, Karla C. S. Queiroz, Jetse Scholma, Susan M. I. Goorden, Jasper J. Anink, C. Arnold Spek, Marianne Hoogeveen‐Westerveld, Marco J. Bruno, Mark D. Nellist et al. · 2015 · Scientific Reports
26. Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
    Arvind Singh Mer, Emily M. Heath, Seyed Ali Madani Tonekaboni, Nergiz Dogan-Artun, Sisira Kadambat Nair, Alex Murison, Laura García‐Prat, Liran I. Shlush, Rose Hurren, Véronique Voisin et al. · 2021 · Nature Communications
27. The Neurobiology of Tuberous Sclerosis Complex
    Kevin C. Ess · 2006 · Seminars in Pediatric Neurology
28. Stromal Liver Kinase B1 [STK11] Signaling Loss Induces Oviductal Adenomas and Endometrial Cancer by Activating Mammalian Target of Rapamycin Complex 1
    Pradeep Singh Tanwar, Tomoko Kaneko-Tarui, LiHua Zhang, Yoshihiro Tanaka, Christopher P. Crum, Jose M. Teixeira · 2012 · PLoS Genetics
29. Targeted Therapy With Imatinib: Hits and Misses?
    Margaret von Mehren · 2004 · Journal of Clinical Oncology
30. The role of NF-κB and AhR transcription factors in lead-induced lung toxicity in human lung cancer A549 cells
    Ibraheem Mohammed Attafi, Saleh A. Bakheet, Hesham Mohamed Korashy · 2019 · Toxicology Mechanisms and Methods
31. Tumoral angiogenesis and breast cancer
    Parham Khosravi Shahi, Alicia Soria Lovelle, G. Pérez Manga · 2009 · Clinical & Translational Oncology
32. Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications—The Role of Molecular Dynamics Simulation
    Jaison Jeevanandam, Kei Xian Tan, Michael K. Danquah, Haobo Guo, Andrew Turgeson · 2019 · Biotechnology Journal
33. Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies
    Andrew Xiuxuan Zhu, Dan Gabriel Duda, Dushyant V. Sahani, Rakesh K. Jain · 2009 · The Cancer Journal
34. New treatment approaches in renal cell carcinoma
    Gaetano Facchini, Francesco Perri, Michele Caraglia, Carmela Pisano, Stefano Striano, Luigi Marra, Francesco Fiore, Pasquale Aprea, Sandro Pignata, Rosario Vincenzo Iaffaioli · 2009 · Anti-Cancer Drugs
35. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment
    Carlo L. Bello, May Garrett, Laurie Jill Sherman · 2010 · Cancer Chemotherapy and Pharmacology
36. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
    Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida et al. · 2012 · Investigational New Drugs
37. Rational design, synthesis and molecular modeling studies of novel anti-oncological alkaloids against melanoma
    Adel S. Girgis, Siva S. Panda, Aladdin M. Srour, Hanaa Farag, Nasser S. M. Ismail, Mohamed Elgendy, Amal Kamal Abdel‐Aziz, ALAN ROY KATRITZKY · 2015 · Organic & Biomolecular Chemistry
38. Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer
    Neelesh Sharma, Nathan A. Pennell, Myles S. Nickolich · 2014 · Investigational New Drugs
39. Targeting mTOR in cancer: renal cell is just a beginning
    Hamdy A. Azim, Hatem A. Azim, Bernard J. Escudier · 2010 · Targeted Oncology
40. Linifanib: current status and future potential in cancer therapy
    Caterina Aversa, Francesco Leone, G Zucchini · 2015 · Expert Review of Anticancer Therapy
41. Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma)
    Matthew E. Bourcier, Aaron I. Vinik · 2013 · Pancreas
42. Sunitinib: from charge-density studies to interaction with proteins
    Maura Malińska, Katarzyna Natalia Jarzembska, Anna M. Goral · 2014 · Acta Crystallographica Section D Biological Crystallography
43. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Francisco Robert, Alan Sandler, Joan H. Schiller et al. · 2009 · Cancer Chemotherapy and Pharmacology
44. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma
    Kevin P. Horn, Jeffrey T. Yap, Neeraj Agarwal, Kathryn A. Morton, D.J. Kadrmas, Britney E. Beardmore, Regan I. Butterfield, Kenneth M. Boucher, John M. Hoffman · 2015 · Cancer Imaging
45. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
    Colin Brooks, Tommy Sheu, Kathleen A. Bridges · 2012 · Radiation Oncology
46. Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib
    Aaron I. Vinik, Éric Raymond · 2013 · Therapeutic Advances in Gastroenterology
47. Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study
    Daniel J. George, Jean-François Martini, Michael D. Staehler et al. · 2018 · Clinical Cancer Research
48. Ambiguous Effects of Autophagy Activation Following Hypoperfusion/Ischemia
    Michela Ferrucci, Francesca Biagioni, Larisa Ryskalin, Fiona Limanaqi, Stefano Gambardella, Alessandro Frati, Francesco Fornai · 2018 · International Journal of Molecular Sciences
49. Transcriptome profiling analysis reveals that ATP6V0E2 is involved in the lysosomal activation by anlotinib
    Xin Sun, Yuhan Shu, Peiyi Yan, Hongliang Huang, Rui-lan Gao, Mengting Xu, Liqin Lu, Jingkui Tian, Dongsheng Huang, Jianbin Zhang · 2020 · Cell Death and Disease
50. Uncoupling of ER/Mitochondrial Oxidative Stress in mTORC1 Hyperactivation-Associated Skin Hypopigmentation
    Fei Yang, Lingli Yang, Mari Wataya‐Kaneda, Takuji Yoshimura, Atsushi Tanemura, Ichiro Katayama · 2017 · Journal of Investigative Dermatology
51. Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer
    Robert S. Kerbel · 2012 · Journal of Mammary Gland Biology and Neoplasia
52. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies
    Jessica Kaplan Altman, Leonidas C. Platanias · 2008 · Current Opinion in Hematology
53. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents
    Margarita Majem, Cinta Pallarés · 2013 · Clinical & Translational Oncology
54. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
    Katharina ten Freyhaus, Bernhard Homey, Thomas R.M. Bieber · 2008 · British Journal of Dermatology
55. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma
    Edwin Pun Hui, Vivian Wai Yan Lui, Sze Chuen Cesar Wong · 2010 · Investigational New Drugs
56. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations
    Jean‐Yves Blay, Peter Reichardt · 2009 · Expert Review of Anticancer Therapy
57. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study
    Steven G. DuBois, Suzanne Shusterman, Joel M. Reid · 2011 · Cancer Chemotherapy and Pharmacology
58. Tuberous sclerosis complex: a brave new world?
    Kevin C. Ess · 2010 · Current Opinion in Neurology
59. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases
    Jakub Żołnierek, Paweł Nurzyński, Przemysław Langiewicz · 2009 · Journal of Cancer Research and Clinical Oncology
60. Novel FLT3 tyrosine kinase inhibitors
    Mark J. Levis, Donald Small · 2003 · Expert Opinion on Investigational Drugs
61. Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex
    Hidehiro Takei, Adekunle M. Adesina, Suzanne Zein-Eldin Powell · 2008 · Neuropathology
62. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma
    S. Négrier, E. Raymond · 2012 · Investigational new drugs
63. Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer
    Nathalie Théou–Anton, Sandrine J. Faivre, Chantal Dreyer · 2009 · Drug Safety
64. Everolimus – a new approach in the treatment of renal cell carcinoma
    Tim G Eisen · 2010 · Cancer Management and Research
65. Target of Rapamycin
    Patrick B. Dennis, George Thomas · 2002 · Current Biology
66. New Chemical Scaffolds for Human African Trypanosomiasis Lead Discovery from a Screen of Tyrosine Kinase Inhibitor Drugs
    Ranjan Behera, Sarah M. Thomas, Kojo Mensa‐Wilmot · 2014 · Antimicrobial Agents and Chemotherapy
67. Hypertension in cancer patients treated with anti-angiogenic based regimens
    Yishay Wasserstrum, Ran Kornowski, Pia Raanani, Avi Leader, Oren Pasvolsky, Zaza Iakobishvili · 2015 · Cardio-Oncology
68. Structure–activity relationship studies of indolin‐2‐one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents
    Mozhdeh Yousefian, Razieh Ghodsi · 2020 · Archiv der Pharmazie
69. Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib
    Yi Ling Teo, Xiu Ping Chue, Noan Minh Chau · 2014 · Targeted Oncology
70. Investigational agents in development for the treatment of ovarian cancer
    Shannon Neville Westin, Thomas J. Herzog, Robert Louis Coleman · 2012 · Investigational New Drugs
71. Early development of sunitinib in hepatocellular carcinoma
    Andrew Xiuxuan Zhu, Éric Raymond · 2008 · Expert Review of Anticancer Therapy
72. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice
    Jingyun Li, Yupeng Ren, Yuan Yin, Shuangmin Ji, Shupei Zhou, Lijie Wang, Zhen-zhen Mou, Liang Li, Wei Lu, Tianyan Zhou · 2016 · Acta Pharmacologica Sinica
73. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy
    Andrew D. Smith, Xu Zhang, Jason A. Bryan, Frederico Souza, Manohar S. Roda, Reza Sirous, Haowei Zhang, Amit Vasanji, Michael Griswold · 2016 · Radiology
74. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
    Devalingam Mahalingam, Claudia M. Espitia, Ernest C. Medina, Juan Esquivel, Kevin R. Kelly, David J. Bearss, Gavin S. Choy, Pietro Taverna, Jennifer S. Carew, Francis Joseph Giles et al. · 2011 · British Journal of Cancer
75. Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study
    Thomas Bachelot, José Á. García-Sáenz, Sunil Verma et al. · 2014 · BMC Cancer
76. Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma
    Atsunari Kawashima, Akira Tsujimura, Hitoshi Takayama et al. · 2012 · Medical Oncology
77. Synthesis and DFT studies of an antitumor active spiro-oxindole
    Adel S. Girgis, Ahmed F. Mabied, Jacek Stawiński · 2015 · New Journal of Chemistry
78. The role of TSC2 in breast cancer: a literature review
    Qiao‐Yan Zhu, Zhe-Min He, Wen‐Ming Cao, Bei Li · 2023 · Frontiers in Oncology
79. Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
    Kewn‐wook Lee, S. R. Park, Do‐Youn Oh et al. · 2013 · Investigational New Drugs
80. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
    Charles S. Harmon, Samuel E. DePrimo, Éric Raymond et al. · 2011 · Journal of Translational Medicine
81. Mutational analysis of TSC1 and TSC2 in Japanese patients with tuberous sclerosis complex revealed higher incidence of TSC1 patients than previously reported
    Yo Niida, Akiko Wakisaka, Takanori Tsuji, Hiroshi Yamada, Mondo Kuroda, Yusuke Mitani, Akiko Okumura, Ayano Yokoi · 2013 · Journal of Human Genetics
82. Sunitinib for the management of advanced renal cell carcinoma
    Bernard J. Escudier · 2010 · Expert Review of Anticancer Therapy
83. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor
    Suzanne George · 2007 · Current Oncology Reports
84. Panax ginseng exerts antiproliferative effects on rat hepatocarcinogenesis
    Hyemee Kim, Hae-Jeung Lee, Dae Joong Kim · 2013 · Nutrition Research
85. Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models
    Salahaldin A. Tahir, Shinji Kurosaka, Ryuta Tanimoto, Alexei A. Goltsov, Sanghee Park, Timothy C. Thompson · 2013 · Cancer Biology & Therapy
86. Antiangiogenic therapy in nonsmall cell lung cancer
    Martin E Gutierrez, Giuseppe Giaccone · 2008 · Current Opinion in Oncology
87. Quantification of Sunitinib and N-Desethyl Sunitinib in Human EDTA Plasma by Liquid Chromatography Coupled With Electrospray Ionization Tandem Mass Spectrometry
    Nienke A. G. Lankheet, Neeltje Steeghs, Hilde Rosing · 2013 · Therapeutic Drug Monitoring
88. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways
    Yuichi Aita, Kiyo‐aki Ishii, Yuria Saito, Tatsuhiko Ikeda, Yasushi Kawakami, Hitoshi Shimano, Hisato Hara, Kazuhiro Takekoshi · 2012 · American Journal of Physiology-Endocrinology and Metabolism
89. Harnessing the potential of multimodal radiotherapy in prostate cancer
    Yiannis Philippou, Hanna T. Sjoberg, Alastair D.G. Lamb, Philip Camilleri, Richard J. Bryant · 2020 · Nature Reviews Urology
90. Therapeutic targeting of receptor tyrosine kinases in lung cancer
    Nicholas W. Choong, Patrick C Ma, Ravi Salgia · 2005 · Expert Opinion on Therapeutic Targets
91. Bevacizumab in high-grade gliomas: past, present, and future
    Richard Charles Curry, Saurabh Dahiya, Vyshak Alva Venur, Jeffrey J. Raizer, Manmeet Singh Ahluwalia · 2015 · Expert Review of Anticancer Therapy
92. Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise Aysel Yardley, E. Claire Dees, Steve Myers · 2012 · Breast Cancer Research and Treatment
93. Gastrointestinal Stromal Tumors
    Piotr Lukasz Rutkowski, Maria Dêbiec‐Rychter, W. Ruka · 2008 · Molecular Diagnosis & Therapy
94. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex
    Fei Yang, Lingli Yang, Mari Wataya‐Kaneda, Junya Hasegawa, Tamotsu Yoshimori, Atsushi Tanemura, Daisuke Tsuruta, Ichiro Katayama · 2017 · Journal of Dermatological Science
95. KIT gene in pediatric osteosarcomas: Could it be a new therapeutic target?
    Natacha Entz‐Werlé, Marie‐Pierre Gaub, Thomas Lavaux et al. · 2007 · International Journal of Cancer
96. Dysregulation of the MMP/TIMP Proteolytic System in Subependymal Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex: Modulation of MMP by MicroRNA-320d In Vitro
    Anika Bongaarts, Jody M. de Jong, Diede W. M. Broekaart, Jackelien van Scheppingen, Jasper J. Anink, Caroline Mijnsbergen, Floor E. Jansen, Wim G.M. Spliet, Wilfred F.A. den Dunnen, Victoria‐Elisabeth Gruber et al. · 2020 · Journal of Neuropathology & Experimental Neurology
97. Emerging drugs for small-cell lung cancer
    Giulio Metro, Federico Cappuzzo · 2009 · Expert Opinion on Emerging Drugs
98. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
    Marc Dror Michaelson, Andrew Xiuxuan Zhu, David P. Ryan et al. · 2013 · British Journal of Cancer
99. Safety profile of new anticancer drugs
    Laura Mansi, Antoine Thiery-Vuillemin, Thierry Nguyen, Fernando Bazán, Fabien Calcagno, Julien Rocquain, Martin Demarchi, Cristian Villanueva, Tristan Maurina, Xavier B. Pivot · 2010 · Expert Opinion on Drug Safety
100. LAM cells biology and lymphangioleiomyomatosis
     Irmina Grzegorek, Katarzyna Drożdż, Marzenna Podhorska‐Okołów · 2013 · Folia Histochemica et Cytobiologica